Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Trial
Official title:
A Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment
Verified date | May 2024 |
Source | Ohio State University Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial examines a group-mediated cognitive behavioral resistance exercise intervention in head and neck cancer patients who are undergoing chemoradiation treatment. Chemoradiation is the established standard of care for locally advanced head and neck cancer patients. However, many head and neck cancer patients experience clinically meaningful declines in muscle mass, physical function, and quality of life during and following treatment. Resistance exercise has been shown to improve muscle mass, body composition, and physical function when integrated with appropriate standard of care nutritional counseling/supplementation. This trial may help researchers determine the important of integrating exercise interventions with routine cancer care.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | December 31, 2024 |
Est. primary completion date | February 20, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with locally advanced human papillomavirus (HPV)+ stage III-IV head and neck (HN) squamous cell carcinomas undergoing concurrent chemotherapy and radiation therapy. Patients with prior cancers or post-surgical patients needing adjuvant therapy will not be allowed to participate in this study - Undergoing planned course of standard of care CRT for a total of 33 to 35 RT fractions (six and a half or seven weeks of treatment) - Adults 18 years old (yo) or older who have clearance from their primary care provider (PCP) or medical oncologist to participate in resistance exercises during treatment. These patients will be monitored very closely on a weekly basis during the trial - All participants must be free of severe heart or systemic disease or medical contraindications that would make supervised RE participation unsafe - Receive medical clearance to participate from treating primary care physician or Medical Oncologists - Ability to understand and the willingness to sign a written informed consent - Willing and physically able to participate in RE Exclusion Criteria: - Severe heart or systemic disease or medical contraindications to exercise - Diagnosis of cancer other than HNCa - Musculoskeletal/Neurological disorder inhibiting them from safe exercise - Pregnant or nursing women - Unable to give informed consent |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment rates | Number of patients agreed to participate by signing the informed consent | At baseline | |
Primary | Adherence of Intervention | Adherence will be defined via session attendance and compliance with the prescribed sets, repetitions, and loads of the RE prescription as assessed using exercise logs, upon which participants will record all exercise performed at the center or independently.. | At 3-month | |
Primary | Adherence of Intervention | Adherence will be defined via session attendance and compliance with the prescribed sets, repetitions, and loads of the RE prescription as assessed using exercise logs, upon which participants will record all exercise performed at the center or independently.. | At 6-month | |
Primary | Incidence of adverse events | Monitored by direct observation and or patient reporting of signs and symptoms using NCI CTCAE version 5 | At 3-month | |
Primary | Incidence of adverse events | Monitored by direct observation and or patient reporting of signs and symptoms using NCI CTCAE version 5 | At 6-month | |
Primary | Retention rates | Rates will be calculated prospectively throughout the trial | At 3-month | |
Primary | Retention rates | Rates will be calculated prospectively throughout the trial | At 6-month | |
Primary | Functional Battery | Functional Battery Objective Functional Performance will be assessed using 3 valid and reliable timed performance-related mobility tasks: 400-meter walk (the primary outcome), stair-climb, and lift and carry task. Assessments of Mobility-Related Self-Efficacy to complete each functional task will also be completed with the tests. | At 3-month | |
Primary | Functional Battery | Functional Battery Objective Functional Performance will be assessed using 3 valid and reliable timed performance-related mobility tasks: 400-meter walk (the primary outcome), stair-climb, and lift and carry task. Assessments of Mobility-Related Self-Efficacy to complete each functional task will also be completed with the tests. | At 6-month | |
Primary | Patient Reported Outcomes (Quality of Life/Fatigue/Physical Function) | QoF will be assessed using both global and disease-specific measures including the satisfaction with life scale, the SF-12, the Functional Assessment of Cancer Therapy - Head and Neck (FACT - HN) and the EORTC Quality of Life scale. Fatigue symptoms will be assessed with the Brief Fatigue Inventory (BFI). | At 3-month | |
Primary | Patient Reported Outcomes (Quality of Life/Fatigue/Physical Function) | QoF will be assessed using both global and disease-specific measures including the satisfaction with life scale, the SF-12, the Functional Assessment of Cancer Therapy - Head and Neck (FACT - HN) and the EORTC Quality of Life scale. Fatigue symptoms will be assessed with the Brief Fatigue Inventory (BFI). | At 6-month | |
Primary | Muscular strength | Muscular strength will be assessed using standardized one-repetition maximum testing protocols for the chest press and leg extension exercises. | At 3-month | |
Primary | Muscular strength | Muscular strength will be assessed using standardized one-repetition maximum testing protocols for the chest press and leg extension exercises. | At 6-month | |
Primary | Anthropometric measurements | Anthropometric measurements are a series of quantitative measurements of the muscle, bone, and adipose tissue used to assess the composition of the body. The core elements of anthropometry are height, weight, body mass index (BMI), body circumferences (waist, hip, and limbs), and skinfold thickness. Anthropometric measurements will be taken in a consultation room to ensure the privacy of the participant. | At 3-month | |
Primary | Anthropometric measurements | Anthropometric measurements are a series of quantitative measurements of the muscle, bone, and adipose tissue used to assess the composition of the body. The core elements of anthropometry are height, weight, body mass index (BMI), body circumferences (waist, hip, and limbs), and skinfold thickness. Anthropometric measurements will be taken in a consultation room to ensure the privacy of the participant. | At 6-month | |
Primary | Body composition | Body composition will be assessed using dual-energy x-ray absorptiometry (DEXA; GE Health Care Lunar, Madison, WI) for all outcome measures. The DEXA scans will be used to determine total body composition including bone-mineral density, as well as, percentage body fat and fat-free mass for all body regions. | At 3-month | |
Primary | Body composition | Body composition will be assessed using dual-energy x-ray absorptiometry (DEXA; GE Health Care Lunar, Madison, WI) for all outcome measures. The DEXA scans will be used to determine total body composition including bone-mineral density, as well as, percentage body fat and fat-free mass for all body regions. | At 6-month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03426657 -
Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC
|
Phase 2 | |
Recruiting |
NCT05172245 -
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT04949503 -
A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
|
||
Completed |
NCT04870840 -
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT04541355 -
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
|
Phase 2 | |
Recruiting |
NCT03649048 -
Low-Dose Weekly vs High-Dose Cisplatin
|
N/A | |
Recruiting |
NCT05724602 -
Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05773079 -
Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05861557 -
Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05527782 -
Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05376553 -
Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 | |
Withdrawn |
NCT03875053 -
Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer
|
N/A | |
Recruiting |
NCT04892173 -
NBTXR3 With or Without Cetuximab in LA-HNSCC
|
Phase 3 | |
Withdrawn |
NCT05743270 -
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
|
Phase 2 | |
Recruiting |
NCT06240689 -
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
|
Phase 2 | |
Suspended |
NCT04454489 -
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
|
Phase 2 | |
Completed |
NCT01689194 -
Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT05245682 -
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
|
Early Phase 1 | |
Recruiting |
NCT04947241 -
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
|
Phase 1 |